Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
<i>PTEN</i> Inhibits Cell Proliferation, Promotes Cell Apoptosis, and Induces Cell Cycle Arrest via Downregulating the PI3K/AKT/<i>hTERT</i> Pathway in Lung Adenocarcinoma A549 Cells.
|
27822469 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA.
|
22707299 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K/Akt signaling pathway.
|
24117074 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lung adenocarcinoma is the most common subtype of Non small cell lung cancer in which the PI3K/Akt cascade is frequently deregulated.
|
29558998 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A PIK3CA mutation was detected in 7 of 115 cases of metastatic ADC (6.1%).
|
27007084 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A concurrent PIK3CA mutation is a poor prognostic factor in patients with advanced EGFR-mutant or KRAS-mutant lung adenocarcinomas.
|
26334752 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
|
22684718 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Disrupting the RAS-PI3K interaction inhibits activation of both AKT and RAC1 in EGFR-mutant lung cancer cells, leading to reduced growth and survival, and inhibits EGFR-mutant-induced tumor onset and promotes major regression of established tumors in an autochthonous mouse model of EGFR-mutant-induced lung adenocarcinoma.
|
30590030 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Elevated PD-L1 mRNA expression in lung adenocarcinoma is associated with EGFR mutation and may be mediated through the PI3K-AKT pathway.
|
31436252 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
|
25596284 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Finally, in nude mice bearing established HCT15 and H1975 subcutaneous tumor xenografts, the combined treatment with pimasertib and BEZ235 (a dual PI3K/mTOR inhibitor) or with sorafenib caused significant tumor growth delays and increase in mice survival as compared to single agent treatment.
|
23629727 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Finally, Western blot analysis was performed to measure the expressions of PI3K, p-PI3K, AKT, p-AKT, ERK1/2, p-ERK1/2, GSK3β, p-GSK3β, mTOR, and p-mTOR protein in lung adenocarcinoma and squamous cell carcinoma cells.
|
29384143 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Further investigation identified that TSPY1 could directly bind to the promoter of insulin growth factor binding protein 3 (IGFBP3) to inhibit IGFBP3 expression and that downregulation of IGFBP3 increased the activity of PI3K/AKT/mTOR/BCL2 and RAS/RAF/MEK/ERK/JUN signaling in LUAD and LIHC cells.
|
30815935 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-381 overexpression affected the PI3K/Akt pathway and EMT in LA.
|
31646571 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we report measurements of PIK3CA H1047R mutant fraction (MF) in normal colonic mucosa, normal lung, colonic adenomas, colonic adenocarcinomas, and lung adenocarcinomas.
|
28755461 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we have shown that phosphatidylinositol 3-kinase-targeted (PI3K-targeted) therapy suppresses metastasis in a mouse model of Kras/Tp53-mutant lung adenocarcinoma that develops metastatic disease due to high expression of ZEB1.
|
24762440 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
However, MCM gene expression has not been well‑studied in lung adenocarcinoma (LUAD).
|
31545501 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
However, iMDK did not reduce the cell viability of MDK-negative A549 lung adenocarcinoma cells or normal human lung fibroblast (NHLF) cells indicating its specificity. iMDK suppressed the endogenous expression of MDK but not that of other growth factors such as PTN or VEGF. iMDK suppressed the growth of H441 cells by inhibiting the PI3K pathway and inducing apoptosis.
|
23976985 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, analysis of the copy number alterations of these 23 genes revealed correlations between <i>EMSY</i>/<i>CCND1</i>, <i>EMSY</i>/<i>PIK3CA</i>, <i>CCND1</i>/<i>CDKN2A</i>, and <i>CCND1</i>/<i>PIK3CA.</i> Our exploration of integrated copy number and gene expression analysis gives priority to the <i>PTEN</i>-<i>PIK3CA</i> and <i>RB1</i>-<i>CCND1</i> pathways in developing therapeutic strategies for LUAD patients without <i>EGFR</i> mutations or <i>ALK</i> fusion.
|
29581789 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggest that neferine enhances cisplatin -induced autophagic cancer cell death through downregulation of PI3K/Akt/mTOR signaling pro-survival pathway and ROS- mediated Beclin-1 and PI3K CIII independent autophagy in human lung adenocarcinoma (A549 cells).
|
28223119 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this series, 230 resected lung adenocarcinomas from smoker (>100 cigarettes in lifetime) at single center (Shanghai Cancer Center, Shanghai, China) were tested for mutation in EGFR, KRAS, BRAF, HER2, EML4-ALK and PIK3CA.
|
23098378 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1.
|
20855837 |
2010 |
Adenocarcinoma of lung (disorder)
|
0.500 |
Biomarker
|
disease |
BEFREE |
LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.
|
30541897 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Mechanistic analysis revealed that in lung adenocarcinoma cells IFN-γ-induced activation of JAK2-STAT1 and PI3K-AKT pathways.
|
29516506 |
2018 |